---

Olig1 and Olig2, two transcription factors, play regulatory function in the differentiation and specification of oligodendrocyte progenitor cells (OPCs). In this study the effects of electromagnetic fields (EMF) on total protein concentration ( TPC ) and Olig1 and Olig2 expression in the cerebral cortex of mouse was examined. Twenty-one Balb/c mice were separated into three groups: control, EMF and Sham groups (n=7 for each group). The mice were placed inside the solenoid for a daily EMF exposure of 50 Hz, 1 mT for 6 h/day, 7 days/week for 10 days. The Sham group was also located in the same coil with no exposure. Mice were anesthetized after the final exposure session and their cerebral cortex were collected. TPC and the expression of Olig 1 and Olig2 were studied by Bio-Rad protein assay and western blot, respectively. The cerebral cortex samples were removed for further analysis. There was no significant difference in TPC in the EMF treated cortical samples as compared with those from the SHAM and control groups. It was also shown that the expression of Olig1 and Olig2 was increased in the EMF treated cortical extracts as compared with those in controls and SHAM groups. Therefore, it could be concluded that EMF enhances Olig1 and Olig2 expression in the mice cerebral cortex. Moreover, as Olig1 and Olig2 plays important role in the development of oligodendrocyte progenitor cells, it can be deduced that EMF may affect OPC differentiation by increasing the expression of Olig1 and Olig2. Further studies are needed to clarify the extent of EMF impact on oligodendrocyte differentiation.
 
 

---

Breast cancer is the fourth common cancer worldwide and occurs when breast cells begin to uncontrolled division and tumor formation. Angiogenesis is one of the essential factors in cell growth and maintenance of homeostasis in the natural and pathological conditions, while VEGFs are the most critical factors in angiogenesis. MiR-210 plays an important role in the angiogenesis via association with VEGF. Here, the miR-210 expression changes in response to a VEGFB antagonist peptide, called VEGB1, was studied in female BALB/c mice bearing 4T1 cell line induced breast tumor. The treated group received 1mg.kg^-1 and 10mg.kg^-1 of the peptide and the control group received PBS intraperitoneally during two weeks. Both of the animal groups underwent a resection of breast tissue 14 days after treatment and miR-210 expression level was investigated. Statistical analysis by On-way ANOVA showed that the expression level of miR-210 gene had significant differences among the groups treated with various doses of VEGB1. Also, the gene expression was significantly different between peptide-treated groups and control samples (p<0.05). MiR-210 expression level had 42% reduction in mice treated with 1mg.kg^-1 of VEGB1, while 90% was seen in mice treated with 10mg.kg^-1 of VEGB1 showing the inhibitory function of VEGB1 antagonist peptide at different doses.